Oral route for HAE

Why Pharvaris believes its oral compound can stand out in the crowded HAE field

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for.

Pharvaris B.V. brings together team members responsible for developing Firazyr at Jerini AG with veterans of rare disease company Prosensa Holding N.V. to develop a compound that could improve ease of use for HAE patients by treating the disease

Read the full 679 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers